

DMD # 82453

**The Involvement of the Mitochondrial Amidoxime Reducing Component (mARC) in the  
Reductive Metabolism of Hydroxamic Acids**

**Carsten Ginsel, Birte Plitzko, Danilo Froiep, Diana A. Stolfa, Manfred Jung, Christian Kubitza,  
Axel J. Scheidig, Antje Havemeyer, Bernd Clement\***

Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, Christian-Albrechts-  
Universität zu Kiel, Gutenbergstraße 76, 24118 Kiel, Germany (CG, BP, DN, AH, BC)

Institute of Pharmaceutical Sciences, Albert-Ludwig-Universität Freiburg, Albertstraße 25, 79104 Freiburg,  
Germany (MJ, DAS)

Zoological Institute – Structural biology, Christian-Albrechts-Universität zu Kiel, Am Botanischen Garten 1-  
9, 24118 Kiel, Germany (CK, AJS)

DMD # 82453

**Running Title:** Reduction of hydroxamic acids by mARC

**To whom correspondence should be addressed:** Bernd Clement, Department of Pharmaceutical and Medicinal Chemistry, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Gutenbergstraße 76, 24118 Kiel, Germany, Tel.: +494318801129; Fax: +494318801352; Email: bclement@pharmazie.uni-kiel.de

**Text pages:**

**Tables:** 1

**Figures:** 5

**References:** 45

**Words Abstract:** 243

**Words Introduction:** 665

**Words Discussion:** 672

**Nonstandard abbreviations:**

ACN = acetonitrile, BCA = bicinchoninic acid, bs = broad singlet, CI = chemical ionization, CYB5B = cytochrome b5 type B, CYB5R3 = NADH-cytochrome b5 reductase 3, d = doublet, dd = double doublet, DMSO = dimethyl sulfoxide, DS116 = N'-phenyloctanediamide, DS92 = 8-oxo-8-(phenylamino)octanoic acid, dt = double triplet, EI = electron ionization, ESI = electrospray ionization, FBS = fetal bovine serum, HDACs = histone deacetylases, HPLC = high performance liquid chromatography, J = coupling constant in Hz, m = multiplet, LOQ = limit of quantification, mARC = mitochondrial amidoxime reducing component, mp = melting point, NMR = nuclear magnetic resonance, PCI = positive chemical ionization, rt = retention time, s = singlet, t = triplet, TLC = thin layer chromatography, UV = ultra violet,  $\delta$  = chemical shift in ppm

DMD # 82453

## Abstract

The mitochondrial amidoxime reducing component is a recently discovered molybdenum enzyme in mammals which, in concert with the electron transport proteins cytochrome b5 and NADH cytochrome b5 reductase, catalyzes the reduction of *N*-oxygenated structures. This three component enzyme system plays a major role in *N*-reductive drug metabolism. Belonging to the group of *N*-hydroxylated structures, hydroxamic acids are also potential substrates of the mARC-system. Hydroxamic acids show a variety of pharmacological activities and are therefore often found in drug candidates. They can also exhibit toxic properties as is the case for many aryl hydroxamic acids formed during the metabolism of arylamides. Biotransformation assays using recombinant human proteins, subcellular porcine tissue fractions as well as human cell culture were performed. Here the mARC-dependent reduction of the model compound benzhydroxamic acid is reported in addition to the reduction of three drugs. In comparison to other known substrates of the molybdenum depending enzyme system (e.g. amidoxime prodrugs) the conversion rates measured here are slower, thereby reflecting the mediocre metabolic stability and oral bioavailability of distinct hydroxamic acids. Moreover, the toxic *N*-hydroxylated metabolite of the analgesic phenacetin, *N*-hydroxyphenacetin, is not reduced by the mARC-system under the chosen conditions. This confirms the high toxicity of this component, as it needs to be detoxified by other pathways. This work highlights the need to monitor the *N*-reductive metabolism of new drug candidates by the mARC-system when evaluating the metabolic stability of hydroxamic acid-containing structures or the potential risks of toxic metabolites.

DMD # 82453

## Introduction

Hydroxamic acids are a class of substances with a variety of biological activities, including antibiotic (Barb et al., 2007; Halouska et al., 2014) and anti-inflammatory activities (Brogden et al., 1975), along with inhibitory properties towards metalloproteinases (Dalvie et al., 2008; Verma, 2012) and histone-deacetylases (HDACs) (Dokmanovic et al., 2007; Zhang and Zhong, 2014). The latter is of particular interest, as inhibitors of HDACs show antineoplastic activities and are currently applied in cancer treatment with new candidates under development (Wagner et al., 2010; Zhang and Zhong, 2014). Examples are vorinostat (suberoylanilide hydroxamic acid = SAHA) which is marketed as Zolinza<sup>®</sup> for the treatment of T-cell lymphoma and Panabinstat (Farydak<sup>®</sup>) which has just been approved (Raedler, 2016).

Applying compounds with hydroxamic acids in therapy requires a reasonable level of metabolic stability. One expectable metabolic pathway, besides conjugation reactions, is hydrolysis to the corresponding carboxylic acid (Liu et al., 2014). As shown in Figure 1, another likely metabolic conversion is the reduction of hydroxamic acids to the corresponding amide (Lowenthal, 1954; Hirsch and Kaplan, 1961; Kitamura and Tatsumi, 1985; Kiesel et al., 2013). For example, metabolism studies of CP544439, a hydroxamic acid-containing matrix metalloproteinase inhibitor, revealed the formation of the amide, the glucuronide and the carboxylic acid as the main metabolites of the orally administered drug (Dalvie et al., 2008). Besides their pharmacological advantages, aryl hydroxamic acids have been shown to possess toxic and mutagenic properties (Miller et al., 1961; Vaught et al., 1981). For example, the analgesic drug 'Phenacetin' is *N*-hydroxylated during metabolism to yield *N*-hydroxyphenacetin (Hinson and Mitchell, 1976; Wirth et al., 1980). Phenacetin was withdrawn from the market because it was found to induce severe renal papillary necrosis and tumors of the renal pelvis and bladder in humans (Liu et al., 1972; Bengtsson et al., 1978). *N*-hydroxyphenacetin has been held responsible for these severe effects as it conducts similar pathways to many aromatic amines leading to the formation of DNA adducts (Vaught et al., 1981). *In vivo* and *in vitro*, *N*-hydroxyphenacetin is metabolized to Phenacetin (Fischbach and Lenk, 1985). The enzymatic basics of the reductive metabolism remain undetermined. The involvement of the cytochrome P450 isoform 2S1 in this reductive metabolism could be excluded (Wang and Guengerich, 2013).

It is well accepted that the mitochondrial amidoxime-reducing component 'mARC', together with the

## DMD # 82453

electron transport proteins cytochrome b5 and NADH-cytochrome b5 reductase, forms an *N*-reductive three component enzyme system located in the outer mitochondrial membrane which plays a major role in *N*-reductive drug metabolism. It has been shown after *in vitro* reconstitution and in cell culture that the mARC-system is responsible for the reduction of various *N*-hydroxylated compounds like amidoximes, *N*-hydroxyguanidines or sulfhydroxamic acids, hydroxylamines and *N*-oxides (Plitzko et al., 2013; Ott et al., 2015). Our laboratory has recently shown that mARC is a mitochondrial, molybdenum-containing enzyme (Havemeyer et al., 2006). All of the currently analyzed and completely annotated mammalian genomes code for two mARC proteins (mARC1 and mARC2) which share a high degree of sequence identity to each other (Wahl et al., 2010). Though the endogenous function of mARC is still not fully understood, mARC proteins are assumed to be involved in detoxification of mutagenic and toxic aromatic hydroxylamines like *N*-hydroxylated DNA-base analogs (Krompholz et al., 2012; Plitzko et al., 2015). The involvement in energy and NO metabolism has been discussed (Kotthaus et al., 2011; Neve et al., 2012; Jakobs et al., 2014; Sparacino-Watkins et al., 2014). In this study we examined whether the mARC-system is also capable of reducing hydroxamic acids and is thus involved in the metabolic conversion of this substance class. We assayed the *N*-reduction of the model substrate benzhydroxamic acid and of four relevant pharmaceutical compounds (vorinostat, bufexamac and CP544439 as drugs and *N*-hydroxyphenacetin as a toxic drug metabolite) by performing biotransformation assays in the reconstituted recombinant human *N*-reductive system and in subcellular porcine liver fractions. Additionally, by performing metabolism studies and RNAi-mediated down-regulations of mARC in HEK-293 cells, the physiological relevance of the *N*-reduction of hydroxamic acids in human cell metabolism was evaluated.

DMD # 82453

## Materials and Methods

**Reagents and cell lines.** Unless otherwise stated all chemicals were purchased from Carl Roth GmbH & co. KG (Karlsruhe, Germany), Sigma Aldrich or Fluka and used without further purification. Methanol (HPLC grade) was from JT Baker (Deventer, Netherlands). Acetonitrile (HPLC grade) was from Honeywell (Seelze, Germany). Benzoic acid and chlorosulfonic acid were from Merck KGaA (Darmstadt, Braunschweig). Ethyl 4-aminotetrahydro-2H-pyran-4-carboxylate hydrochloride and 4-fluorophenoxybenzene were from abcr (Karlsruhe, Germany). 4-nitrophenetole, 4-butoxyphenylacetic acid and sodium 1-octanesulfonate were from TCI (Zwijndrecht, Belgium). HEK-293 human embryonic kidney cells were purchased from Cell Lines Service (Eppelheim, Germany). Opti-MEM, minimum essential medium, sodium pyruvate solution, sodium bicarbonate, minimum Eagles's medium nonessential amino acids, FBS, trypsin, L-glutamine, PBS, Lipofectamine RNAiMAX, Stealth Select RNAi siRNA targeting human MOSC1 (MOSC1HSS127704), and Stealth Select RNAi siRNA negative control were obtained from Invitrogen (Germany). ONTARGETplus SMARTpool siRNA targeting human MOSC2 was purchased from Thermo Scientific. Complete protease inhibitor cocktail was acquired from Roche Applied Science (Mannheim, Germany). Benzamidoxime was synthesized from benzonitrile and hydroxylamine (Krüger, 1885). For the synthesis of CP544439 (4-((4-(4-fluorophenoxy)phenyl)-sulfonylamino)tetrahydropyran-4-carboxylic acid) and its metabolites see supplemental data.

**Synthesis of vorinostat (suberoanilohydroxamic acid) and metabolites.** Chromatographic separations were performed on silica gel (15–40 mesh, Merck) using flash methodology. Reaction progress was monitored by analytical TLC on pre-coated silica gel (Kieselgel 60 F254) plates, and spots were detected by UV light ( $\lambda$  254 nm). mp of the final target HDAC inhibitors were determined by the open capillary method on a Stuart-Scientific SMP3 electrothermal apparatus and are uncorrected.  $^1\text{H}$  NMR spectra were recorded in the indicated deuterated solvents on a Bruker Avance DRX 400 MHz spectrometer and  $^{13}\text{C}$  NMR on a Varian 100 MHz. Signals due to OH and NH protons were located by deuterium exchange with  $\text{D}_2\text{O}$ . EI- and CI-mass spectra were measured with a TSQ700 mass spectrometer (Thermoelectron). ESI- and PCI-mass spectra were recorded with a LCQ-Advantage mass spectrometer. In all cases, spectroscopic data are in agreement with known compounds and assigned structures. HPLC purity determinations were performed on a JASCO HPLC system under isocratic conditions, using a Phenomenex Synergi Hydro RP-C18 column (250 mm x 4.6 mm, 4  $\mu\text{m}$  particle size).

## DMD # 82453

Elution was performed using 0.05 % of TFA in water/ACN 60/40 (v/v), at room temperature. The purity of all tested compounds was  $\geq 98\%$ , as measured by HPLC. Injection volumes were 2  $\mu\text{L}$ , flow rate was 0.5 ml/min, detection was performed with UV ( $\lambda = 254\text{nm}$ ). All chromatographic and spectroscopic data were in accordance with literature data.

*Synthesis of vorinostat:* vorinostat was synthesized according to (Mai et al., 2001). Retention time for HPLC was 7.8 min.

*Synthesis of DS92:* DS92 was synthesized by a modification of the procedure described in the literature (Suzuki et al., 2005). Suberic acid (5.00 g, 28.7 mmol) was slowly added to neat freshly distilled aniline (2.70 ml, 30.1 mmol) and the mixture was stirred at 185 °C and left at the same temperature for 2 h. The mixture was cooled to room temperature and a NaOH 2 N aqueous solution was added to set the pH of the mixture at  $\sim 8$ . The suspension was filtered and the filtrate was acidified to pH $\sim 2$ , obtaining a white precipitate that was collected and suspended in warm water (50 °C). The insoluble part was filtered and washed with hot water, yielding DS92 as white pure precipitate (3.93 g, 55 %).  $R_f = 0.35$  (EtOAc/Cy, 8:2); Retention time for HPLC was 14.5 min; mp = 124-126 °C;  $^1\text{H NMR}$  (400 MHz,  $d_6\text{DMSO}$ ):  $\delta$  1.23-1.35 (m, 4H), 1.42-1.52 (m, 2H), 1.54-1.63 (m, 2H), 2.20 (t, J = 7.4 Hz, 2H), 2.29 (t, J = 7.4 Hz, 2H), 7.01 (tt, J = 7.6; J = 1.1 Hz, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.58 (dd, J = 8.7; J = 1.1 Hz, 2H), 9.85 (s, 1H), 11.97 (br s, 1H); LRMS (ESI) m/z 248.1 [M-H].

## DMD # 82453

*Synthesis of DS116:* DS116 was obtained by a fast two-step synthesis starting from the carboxylic acid derivative DS92, which is transformed using thionyl chloride into the corresponding acyl chloride, further reacted into the target according to an already described procedure (Wright and Corbett, 1993). To a solution of 8-oxo-8-(phenylamino)octanoic acid (0.30 g, 1.2 mmol) in dry DCM (3 ml) thionyl chloride (330  $\mu$ l, 4.6 mmol) was slowly added at room temperature. The solution was heated to reflux for 3 h and later a stream of nitrogen was used to remove the solvent and the excess of thionyl chloride. To the crude product was added a solution of concentrated aqueous ammonia solution (1.03 ml, 26.4 mmol) and  $\text{NH}_4\text{Cl}$  (0.22 g, 4.1 mmol) in 1 ml of water and the mixture was stirred at 20 °C for 8 h. The reaction was quenched with  $\text{NaBH}_4$  (23 mg, 0.6 mmol) and after 1 h at room temperature HCl 2 N aqueous solution was added dropwise to pH~2. The precipitate was collected to give DS116 as white powder (0.24 g, 80 %).  $R_f = 0.30$  (DCM/ $\text{Et}_2\text{O}$ /MeOH/, 9.5:1:0.5); Retention time for HPLC was 9.18 min; mp = 161-163°C;  $^1\text{H-NMR}$  (400 MHz,  $\text{DMSO-d}_6$ ):  $\delta$  1.22-1.34 (m, 4H), 1.44-1.52 (m, 2H), 1.63-1.53 (m, 2H), 2.03 (t, J = 7.4 Hz, 2H), 2.29 (t, J = 7.4 Hz, 2H), 6.68 (br s, 1H), 7.01 (t, J = 7.4, 1H), 7.22 (br s, 1H), 7.28 (t, J = 7.8 Hz, 2H), 7.58 (d, J = 7.8 Hz, 2H), 9.85 (s, 1H); LRMS (ESI) m/z 247.1 [ $\text{M-H}$ ].

**Synthesis of *N*-hydroxyphenacetin.** *N*-hydroxyphenacetin was prepared using a previously reported procedure with minor modifications (Hinson and Mitchell, 1976). 4-Nitrophenetole (2.0 g, 11.96 mmol) and  $\text{NH}_4\text{Cl}$  (0.64 g, 11.96 mmol) were dissolved in 40 ml of a  $\text{C}_2\text{H}_5\text{OH}/\text{H}_2\text{O}$  mixture (4:1, v/v) at room temperature. After the addition of Zn dust (3.2 g, 48.94 mmol) the reaction mixture was stirred for 10 minutes. The Zn dust was filtered and washed with 40 ml  $(\text{C}_2\text{H}_5)_2\text{O}$ . The ethereal phase was washed with 50 ml brine and separated from the aqueous phase.  $\text{NaHCO}_3$  (1.6 g, 19.04 mmol) was suspended in 5 ml  $\text{H}_2\text{O}$  at 0 °C and the *N*-hydroxyphenetidine containing ethereal phase was added. 500  $\mu$ l of 2.5 % acetyl chloride in  $(\text{C}_2\text{H}_5)_2\text{O}$  were slowly added over 1 h. The formation of the product was TLC controlled.

*N*-hydroxyphenacetin gave a red, *N*-hydroxyphenetidine a blue spot with  $\text{FeCl}_3$ . After disappearance of the blue spot, 20 ml of  $\text{H}_2\text{O}$  was added and twice extracted with  $(\text{C}_2\text{H}_5)_2\text{O}$ . The combined layers were washed with  $\text{H}_2\text{O}$  and twice with brine. The product was extracted with 100 ml of cold 0.2 M  $\text{NH}_3$ -solution. After neutralization to pH 7.0 with  $\text{NaHCO}_3$  the product was extracted in 300 ml  $(\text{C}_2\text{H}_5)_2\text{O}$ , dried over anhydrous  $\text{Na}_2\text{SO}_4$  and the solvent was evaporated to dryness. *N*-hydroxyphenacetin was recrystallized with  $(\text{C}_2\text{H}_5)_2\text{O}$ /hexane, 15 % yield from 4-nitrophenetole.  $^1\text{H-NMR}$  (300 MHz,  $\text{DMSO-d}_6$ ):  $\delta$  10.48 (s, 1H,



## DMD # 82453

hydroxyl), 7.45 (d, J = 8.7 Hz, aromatic, 2H), 6.91 (d, J = 9.1 Hz, aromatic, 2H), 4.01 (q, J = 7.0 Hz, 2H, H<sub>3</sub>CH<sub>2</sub>-), 2.14 (s, 3H, CH<sub>3</sub>CO-), 1.31 (t, J = 7.0 Hz, 3H, CH<sub>3</sub>CH<sub>2</sub>-); LC-MS (ESI), m/z 196 [M+H]<sup>+</sup>, 178, 150.

**Protein sources.** Subcellular porcine tissue fractions were purified from female pigs as described earlier (Ott et al., 2014). Expression and purification of human mARC1 (reference sequence NP\_073583) and mARC2 (reference sequence NP\_060368), CYB5B (reference sequence NP\_085056) and CYB5R3 (reference sequence NP\_000389) was carried out in *Escherichia coli* as described by Wahl and coworkers (Wahl et al., 2010). Protein content was determined using (BCA) protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer's protocol. Heme content in CYB5B was determined according to the method of Estabrook by recording the difference spectrum of oxidized and NADH-reduced protein (Estabrook and Werringloer, 1978). FAD-content in CYB5R3 was measured at 450 nm according to Whitby after sample preparation by heating at 100 °C for 10 min and centrifugation at 22000 g for 5 min at room temperature (Whitby, 1953). For the quantification of FAD a calibration curve (0.01 mM to 0.1 mM) was used.

**In vitro N-reductive activity assay.** *In vitro* biotransformation assay was carried out at 37 °C in a shaking water bath. Incubation mixture consisted of 100 µg of porcine subcellular fractions in 100 mM potassium phosphate buffer, pH 6.0 or in case of recombinantly expressed human proteins of 7.5 µg mARC1 or mARC2, CYB5B resulting in 75 pmol heme and CYB5R3 resulting in 7.5 pmol FAD in 20 mM MES buffer, pH 6.0. Different substrate concentrations were used and for CP544439, vorinostat and bufexamac 4.0 %, 4.8 % and 8.0 % DMSO were added respectively. After 3 min of pre-incubation, the reaction was started by adding 1 mM NADH, resulting in a total volume of 150 µl. Incubation was stopped after 15 min by adding 150 µl of cold methanol. Afterwards, samples were shaken for 5 min at room temperature and centrifuged for 5 min with 9500 g at room temperature. Supernatants were analyzed by HPLC. For the determination of kinetic parameters with recombinantly expressed human protein the DMSO concentration was kept at the same level and only the substrate concentration was modified.

**HPLC analysis for incubated samples.** The flow rate was kept at 1.0 ml/min and the injection volume was 10 µl for all performed HPLC analysis. All benzhydroxamic acid and CP544439 related samples were

## DMD # 82453

measured on a Waters e2695 Separation Module with a Waters 2998 Photodiode Array Detector and Waters Empower 2 Build 2154 as integration software.

For the separation of benzhydroxamic acid ( $rt = 5.0 \pm 0.2$  min) benzamide ( $rt = 8.1 \pm 0.2$  min) and benzoic acid ( $rt = 12.7 \pm 0.1$  min) a Phenomenex Gemini NX-C18 ( $5 \mu\text{m}$ ),  $150 \times 4.6$  mm with a Phenomenex C18  $4 \times 3.0$  mm pre-column was used. The mobile phase consisted of 50 mM  $\text{KH}_2\text{PO}_4$ , pH 4.6, 10 mM tetramethylammonium chloride and 10 % acetonitrile (v/v). Detection wavelength was 210 nm.

For the separation of CP544439 ( $rt = 4.8 \pm 0.3$  min), deoxy CP544439 ( $rt = 5.9 \pm 0.2$  min) and the carboxylic derivative ( $rt = 7.0 \pm 0.2$  min) a Waters Sunfire C18,  $3.5 \mu\text{m}$ ,  $150 \times 4.6$  mm with a Phenomenex C18  $4 \times 3.0$  mm pre-column was used. Solvent A (0.2 % formic acid in  $\text{H}_2\text{O}$  (v/v)) and Solvent B (0.2 % formic acid in acetonitrile (v/v)) were used. Starting with 60 % A, the gradient changed linearly from 3 min to 7 min to 10 % A. At 11 min A was set to 60 % over 0.5 min. Total runtime was 16 min. Detection wavelength was 247 nm. The column temperature was maintained at  $25^\circ\text{C}$  and sample storage temperature at  $18^\circ\text{C}$ .

All vorinostat, bufexamac, *N*-hydroxyphenacetin and benzamidoxime related samples were measured on a Waters HPLC system consisting of a Waters 717 autosampler, a Waters 1525 pump and a Waters 2487 dual absorbance detector at room temperature. A Phenomenex Gemini NX-C18 ( $5 \mu\text{m}$ ),  $150 \times 4.6$  mm with a Phenomenex C18  $4 \times 3.0$  mm pre-column was used with exception for benzamidoxime where a LiChrospher® 60 RP-select B ( $5 \mu\text{m}$ ),  $250 \times 4$  mm column combined with a Lichrospher 60 RP-select pre-column was used.

For separation of vorinostat ( $rt = 6.7 \pm 0.0$  min), DS116 ( $rt = 8.9 \pm 0.1$  min) and DS92 ( $rt = 18.9 \pm 0.2$  min) the mobile phase consisted of 100 mM  $\text{KH}_2\text{PO}_4$  and 23 % acetonitrile (v/v). The detection wavelength was set to 254 nm.

For separation of bufexamac ( $rt = 16.9 \pm 0.1$  min), deoxy bufexamac ( $rt = 20.9 \pm 0.1$  min) and the carboxylic derivative ( $rt = 28.5 \pm 0.2$  min) the mobile phase consisted of 50 mM  $\text{KH}_2\text{PO}_4$ , pH 4.4, 10 mM tetramethylammonium chloride and 45% methanol (v/v). Detection wavelength was set to 228 nm.

## DMD # 82453

For separation of *N*-hydroxyphenacetin ( $rt = 7.8 \pm 0.2$  min) and phenacetin ( $rt = 9.1 \pm 0.0$  min) the mobile phase consisted of 1 % formic acid in H<sub>2</sub>O (v/v) and 22.5 % acetonitrile (v/v). Detection wavelength was 245 nm.

For separation of benzamidoxime ( $rt = 9.1 \pm 0.3$  min) and benzamidine ( $rt = 15.9 \pm 0.1$  min) the mobile phase consisted of 10 mM sodium 1-octanesulfonate and 20 % acetonitrile. Detection wavelength was 229 nm.

**Cell Culture.** HEK-293 cells, derived from a female human source, were maintained in minimum essential medium supplemented with 10% FBS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 1.5 g/L sodium bicarbonate. The cell line was incubated at 37 °C in 5 % CO<sub>2</sub>.

**siRNA Transfection and Design of Knockdown Experiments.** HEK-293 cells were reverse transfected and mARC-protein down-regulated according to the previous described procedure (Plitzko et al., 2015).

***N*-reductive metabolism of benzhydroxamic acid in HEK 293 cells.** For *N*-reduction studies in HEK-293 the culture medium was removed, and cells were carefully washed and pre-incubated with substrate-free incubation buffer (Hanks' balanced salt solution containing 10 mM HEPES, pH 7.4) at 37 °C for 10 min. After removing the substrate-free incubation buffer, the vital cells were then incubated with benzhydroxamic acid-containing incubation buffer (3 mM, 0.5% (v/v) DMSO) at 37 °C for 180 min. After the designated time, the culture supernatant was carefully removed, centrifuged to eliminate cellular debris and analyzed by HPLC as described above.

**Total Cellular Protein Extraction.** Cellular protein was harvested and protein contents determined as previously described (Plitzko et al., 2015).

**Western Blot analysis.** SDS-PAGE and Western Blot analysis to verify down-regulation of mARC-protein in HEK-293 cells was carried out as described previously (Plitzko et al., 2015).

**Statistical Analysis.** Statistical analyses were carried out using the SigmaPlot 11 software (Systat Software Inc.). The significance of observed differences was evaluated by Bonferroni test. A probability less than 5% was considered to be significant. All experimental values are given as means  $\pm$  S.D.

DMD # 82453

## Results

From all analyzed subcellular fractions, *N*-reductive activity in mitochondria was found to be enhanced compared to other tissue fractions for all *N*-unsubstituted hydroxamic acids (Figure 3). These findings reflect the enrichment of mARC depending enzyme activities in this fraction as published earlier (Krompholz et al., 2012). In the microsomal and cytosolic fractions only minor/no *N*-reductive activity was detectable. By contrast, no reduction of *N*-hydroxyphenacetin could be detected after incubation with the mitochondrial fraction and only minor reduction rates were detected within the cytosolic fraction (data not shown). Besides reduction to the amide, hydrolysis to the corresponding carboxylic acids was monitored and was found to be more pronounced in microsomes compared to other fractions; this indicates the involvement of a microsomal enzymatic system or a non-enzymatic reaction (Figure 3A, D). In the case of bufexamac and CP544439 the microsomal fraction was the only fraction where hydrolysis could be detected to a small extent (data not shown).

To prove the involvement of mARC in the reduction of hydroxamic acids, a cell based siRNA experiment was performed. In HEK-293 cells reductive conversion of benzhydroxamic acid to benzamide occurs in a time-dependent (data not shown) and substrate-dependent manner (Fig. 4A) and followed Michaelis-Menten kinetics ( $v_{\max} = 0.06 \pm 0.01 \text{ nmol benzamide} \cdot \text{min}^{-1} \cdot \text{mg protein}^{-1}$ ). By siRNA-mediated down-regulation of mARC1, benzamide formation decreased dramatically to approximately 30% compared to the negative control (Fig. 4B). Knockdown of mARC2 in HEK-293 cells did not affect the reduction of benzhydroxamic acid in HEK-293 cells. This same behavior is also observed with the model substrate benzamidoxime and is attributed to the low level of mARC2-protein expression in HEK-293 cells (Plitzko et al., 2013). Simultaneous knockdown of both mARC-proteins led to a small, further decrease in *N*-reductive activity than was observed in the mARC1-only knockout experiments. To further elucidate the differences between mARC1 and mARC2 the kinetic parameters  $v_{\max}$  and  $K_M$  were determined with the *in vitro* reconstituted recombinant *N*-reductive system (Figure 5A-D). All hydroxamic acids were clearly reduced to the corresponding amides with the exception of *N*-hydroxyphenacetin. These results are consistent with previous observations in subcellular fractions. Benzhydroxamic acid, bufexamac, CP544439 and vorinostat were exclusively reduced to their corresponding amides; none of the corresponding carboxylic acid products were detected. The reductions obey Michaelis-Menten kinetics for both mARC-proteins. The calculated  $K_M$  and  $v_{\max}$  values are presented in Table 1. The conversion rates of hydroxamic acids are

## DMD # 82453

lower in comparison to the model compound benzamidoxime (e.g. for vorinostat,  $v_{\max}$  is 15 times slower).

For both incubation types with subcellular fractions and recombinant expressed proteins, highest  $v_{\max}$  values were obtained for the model compound benzhydroxamic acid in comparison to all other studied hydroxamic acids.

According to the  $v_{\max}$  values, CP544439 and vorinostat are reduced to the same amount and smallest conversion rates were detected for bufexamac. Vorinostat, bufexamac and CP544439 required the use of DMSO as a solubilizer. Due to the negative influence of high DMSO concentrations in the incubation mixture (see supplemental data), only the minimum amount of DMSO required for solubility was added. In the case of benzhydroxamic acid  $v_{\max}$  was about four times higher with mARC2 than with mARC1 but the  $K_M$  increased seven-fold. Only slight differences of the kinetic parameters for vorinostat and bufexamac were detected for both mARC forms, whereas CP544439 was exclusively reduced by mARC1. In accordance with the results obtained with subcellular liver fractions and RNAi studies all *N*-unsubstituted hydroxamic acids are reduced by mARC.

DMD # 82453

## Discussion

The mARC-containing three component enzyme system is responsible for the reduction of various *N*-hydroxylated compounds (Ott et al., 2015) and the results of our recent investigations demonstrate clearly that hydroxamic acids belong to this class of compounds. The hydroxamate moiety exhibits strong cation chelating properties and thereby possesses the ability to affect a variety of enzymes. Hydroxamic acid moieties are found in a multitude of drugs and drug candidates (Halouska et al., 2014; Zhang and Zhong, 2014). In addition, aryl hydroxamic acids have been shown to possess toxic and mutagenic properties (Miller et al., 1961; Vaught et al., 1981). Therefore, the investigation of the metabolic fate of hydroxamic acids is of particular relevance for further drug developments and for the understanding of detoxification pathways. We could demonstrate that hydroxamic acids can serve as substrates for the mARC-system. The model compound benzhydroxamic acid, as well as three other drugs (vorinostat, bufexamac and CP544439) are reduced to the corresponding amides by porcine mitochondria and the reconstituted recombinant human mARC-system (Table 1). The *N*-reduction observed *in vitro* is also evident in intact human cell metabolism and is mARC-dependent as the siRNA-mediated down-regulation leads to a dramatic decrease in *N*-reductive activity (Fig. 4B). HEK-293 cells were chosen because of the high *N*-reductive activity in renal tissue (Krompholz et al., 2012). However, the *N*-reductive conversion of hydroxamic acids is lower compared to the model compound (benzamidoxime). Amidoximes, used as prodrugs for amidines, are rapidly reduced *in vivo* (Clement et al., 1992). In the case of hydroxamic acids, reduction leads to inactivation because the amide is not able to form strongly chelating complexes. As metabolism studies for CP544439 reveal, the main metabolism pathways of hydroxamic acids *in vivo* are glucuronidation, reduction and hydrolysis (Dalvie et al., 2008). The reduction to the amide is of great physiological relevance, especially in rats, where the amide is the most prevalent metabolite. It has been demonstrated that the aldehyde oxidase is capable of reducing hydroxamic acids to amides (Sugihara et al., 1983a, 1983b; Sugihara and Tatsumi, 1986). Reduction of CP544439 was proposed to be catalyzed by this enzyme as well; studies with human cytosolic liver fractions using the artificial electron donor *N*-methylnicotinamide resulted in a very low conversion rate ( $1.6 \text{ pmol}\cdot\text{min}^{-1}\cdot\text{mg protein}^{-1}$ ) (Obach, 2004). The aldehyde oxidase is located in the cytosol, but we could not detect any *N*-reductive activity in the porcine liver cytosol under our tested conditions (Fig. 5C). Our determined conversion rate with the mitochondrial fraction for CP544439 is about  $2.5 \text{ nmol}\cdot\text{min}^{-1}\cdot\text{mg protein}^{-1}$ , which is more than 1500 times higher than the

## DMD # 82453

previous described cytosolic conversion rate. This finding indicates the important role of mARC in the reduction of hydroxamic acids to the amides. Interestingly, vorinostat has sufficient metabolic stability for therapy and is applied orally, but high doses of 400 mg per day are necessary (Mann et al., 2007). The enhanced lipophilicity of vorinostat compared to benzhydroxamic acid and benzamidoxime could be a pivotal characteristic. The low conversion rates determined for bufexamac, which is a very lipophilic ether compound, support this theory (Fig. 5B). Studies to further elucidate structure activity relationships should be done to evaluate whether lipophilicity is an important feature for enzymatic conversion of hydroxamic acids by the mARC-system and to detect candidates with better stability towards *N*-reduction.

In the case of *N*-hydroxyphenacetin no reduction to the amide by mARC was observed. This is the first investigated hydroxamic acid studied by us so far which is not reduced. However, this could be an explanation for the high toxicity of this compound as it needs to be detoxified by other pathways. The most apparent difference between *N*-hydroxyphenacetin and the other studied hydroxamic acids is the substitution of the nitrogen's hydrogen with the sterically demanding phenyl group. Due to this steric hindrance mARC might not be able to bind and reduce such kind of substrates. This hypothesis needs to be proved by further structure activity studies.

In conclusion, to properly evaluate the metabolic stability of new hydroxamic acid containing drug candidates, metabolism by the mitochondrial mARC-system must be considered.

DMD # 82453

### **Acknowledgement**

Thanks to Timothy Zerk for proofreading the article.

### **Authorship contributions**

*Participated in research design: Clement, Scheidig, Havemeyer*

*Conducted experiments: Ginsel, Plitzko*

*Contributed new reagents or analytical tools: Ginsel, Froriep, Stolfa, Jung*

*Expression and purification of recombinant proteins: Kubitza*

*Performed data analysis: Ginsel, Plitzko*

*Wrote or contributed to the writing of the manuscript: Ginsel, Plitzko, Clement*



DMD # 82453

## References

- Barb AW, McClerren AL, Snehelatha K, Reynolds CM, Zhou P, and Raetz CRH (2007) Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in *Escherichia coli*. *Biochemistry* **46**:3793–3802 doi: 10.1021/bi6025165.
- Bengtsson U, Johansson S, and Angervall L (1978) Malignancies of the urinary tract and their relation to analgesic abuse. *Kidney Int.* **13**:107–113 doi: 10.1038/ki.1978.13.
- Brogden RN, Pinder RM, Sawyer PR, Speight TM, and Avery GS (1975) Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. *Drugs* **10**:351–356.
- Clement B, Immel M, Terlinden R, and Wingen F-J (1992) Reduction of Amidoxime Derivatives to Pentamidine in vivo. *Arch. Pharm. (Weinheim)* **325**:61–62 doi: 10.1002/ardp.19923250114.
- Dalvie D, Cosker T, Boyden T, Zhou S, Schroeder C, and Potchoiba MJ (2008) Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-(4-fluorophenoxy)-benzenesulfonylamino tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: Assessment of the metabolic profile of CP-544439 in plasma and urine of humans. *Drug Metab. Dispos.* **36**:1869–1883 doi: 10.1124/dmd.108.022566.
- Dokmanovic M, Clarke C, and Marks PA (2007) Histone deacetylase inhibitors: Overview and perspectives. *Mol. Cancer Res.* **5**:981–989 doi: 10.1158/1541-7786.MCR-07-0324.
- Estabrook RW and Werringer J (1978) The measurement of difference spectra: Application to the cytochromes of microsomes. *Methods Enzymol.* **52**:212–220.
- Fischbach T and Lenk W (1985) The metabolism of N-hydroxyphenacetin in vitro and in vivo. *Xenobiotica* **15**:915–927 doi: 10.3109/00498258509045045.
- Halouska S, Fenton RJ, Zinniel DK, Marshall DD, Barletta RG, and Powers R (2014) Metabolomics analysis identifies d-Alanine-d-Alanine ligase as the primary lethal target of d-Cycloserine in mycobacteria. *J. Proteome Res.* **13**:1065–1076 doi: 10.1021/pr4010579.
- Havemeyer A, Bittner F, Wollers S, Mendel R, Kunze T, and Clement B (2006) Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme. *J. Biol. Chem.* **281**:34796–34802 doi: 10.1074/jbc.M607697200.
- Hinson JA and Mitchell JR (1976) N-Hydroxylation of phenacetin by hamster liver microsomes. *Drug Metab. Dispos.* **4**:430–435.
- Hirsch PF and Kaplan NO (1961) The conversion of pyridine hydroxamic acids to amides by mouse liver mitochondria. *J. Biol. Chem.* **236**:926–930.
- Jakobs HH, Mikula M, Havemeyer A, Strzalkowska A, Borowa-Chmielak M, Dzwonek A, Gajewska M, Hennig EE, Ostrowski J, and Clement B (2014) The N-reductive system composed of mitochondrial amidoxime reducing component (mARC), cytochrome b5 (CYB5B) and cytochrome b5 reductase (CYB5R) is regulated by fasting and high fat diet in mice. *PLoS ONE* **9**:e105371 doi: 10.1371/journal.pone.0105371.
- Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, and Beumer JH (2013) LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. *J. Pharm. Biomed. Anal.* **81-82**:89–98 doi: 10.1016/j.jpba.2013.03.025.
- Kitamura S and Tatsumi K (1985) Purification of N-hydroxy-2-acetylaminofluorene reductase from rabbit liver cytosol. *Biochem. Biophys. Res. Commun.* **133**:67–74 doi: 10.1016/0006-291X(85)91842-X.
- Kotthaus J, Wahl B, Havemeyer A, Kotthaus J, Schade D, Garbe-Schönberg D, Mendel R, Bittner F, and Clement B (2011) Reduction of N( $\omega$ )-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC). *Biochem. J.* **433**:383–391 doi: 10.1042/BJ20100960.
- Krompholz N, Krischkowski C, Reichmann D, Garbe-Schönberg D, Mendel R-R, Bittner F, Clement B, and Havemeyer A (2012) The mitochondrial Amidoxime Reducing Component (mARC) is involved in detoxification of N-hydroxylated base analogues. *Chem. Res. Toxicol.* **25**:2443–2450 doi: 10.1021/tx300298m.

DMD # 82453

- Krüger P (1885) Ueber Abkömmlinge des Benzenylamidoxims. *Ber. Dtsch. Chem. Ges.* **18**:1053–1060 doi: 10.1002/cber.188501801219.
- Liu L, Detering J-C, Milde T, Haefeli WE, Witt O, and Burhenne J (2014) Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. *J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci.* **964**:212–221 doi: 10.1016/j.jchromb.2014.02.014.
- Liu T, Smith GW, and Rankin JT (1972) Renal pelvic tumour associated with analgesic abuse. *Can. Med. Assoc. J.* **107**:768 passim.
- Lowenthal J (1954) Enzymatic Conversion of Salicylhydroxamic Acid to Salicylamide. *Nature* **174**:36–37 doi: 10.1038/174036a0.
- Mai A, Esposito M, Sbardella G, and Massa S (2001) A new facile and expeditious synthesis of N-hydroxy-N'-phenyloctanediamide, a potent inducer of terminal cytodifferentiation. *Org. Prep. Proced. Int.* **33**:391–394 doi: 10.1080/00304940109356608.
- Mann BS, Johnson JR, Cohen MH, Justice R, and Pazdur R (2007) FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. *Oncologist* **12**:1247–1252 doi: 10.1634/theoncologist.12-10-1247.
- Miller EC, Miller JA, and Hartmann HA (1961) N-Hydroxy-2-acetylaminofluorene: a metabolite of 2-acetylaminofluorene with increased carcinogenic activity in the rat. *Cancer Res.* **21**:815–824.
- Neve EPA, Nordling A, Andersson TB, Hellman U, Diczfalusy U, Johansson I, and Ingelman-Sundberg M (2012) Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria. *J. Biol. Chem.* **287**:6307–6317 doi: 10.1074/jbc.M111.328237.
- Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. *Drug Metab. Dispos.* **32**:89–97 doi: 10.1124/dmd.32.1.89.
- Ott G, Havemeyer A, and Clement B (2015) The mammalian molybdenum enzymes of mARC. *J. Biol. Inorg. Chem.* **20**:265–275 doi: 10.1007/s00775-014-1216-4.
- Ott G, Plitzko B, Krischkowski C, Reichmann D, Bittner F, Mendel RR, Kunze T, Clement B, and Havemeyer A (2014) Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC). *Chem. Res. Toxicol.* **27**:1687–1695 doi: 10.1021/tx500174u.
- Plitzko B, Havemeyer A, Kunze T, and Clement B (2015) The pivotal role of the mitochondrial amidoxime reducing component 2 in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine. *J. Biol. Chem.* **290**:10126–10135 doi: 10.1074/jbc.M115.640052.
- Plitzko B, Ott G, Reichmann D, Henderson CJ, Wolf CR, Mendel R, Bittner F, Clement B, and Havemeyer A (2013) The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells. *J. Biol. Chem.* **288**:20228–20237 doi: 10.1074/jbc.M113.474916.
- Raedler LA (2016) Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma. *Am Health Drug Benefits* **9**:84–87.
- Sparacino-Watkins CE, Tejero J, Sun B, Gauthier MC, Thomas J, Ragireddy V, Merchant BA, Wang J, Azarov I, Basu P, and Gladwin MT (2014) Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2. *J. Biol. Chem.* **289**:10345–10358 doi: 10.1074/jbc.M114.555177.
- Sugihara K, Kitamura S, and Tatsumi K (1983a) Evidence for reduction of hydroxamic acids to the corresponding amides by liver aldehyde oxidase. *Chem. Pharm. Bull.* **31**:3366–3369 doi: 10.1248/cpb.31.3366.
- Sugihara K, Kitamura S, and Tatsumi K (1983b) Involvement of liver aldehyde oxidase in conversion of N-hydroxyurethane to urethane. *J. Pharmacobio-Dyn.* **6**:677–683 doi: 10.1248/bpb1978.6.677.
- Sugihara K and Tatsumi K (1986) Participation of liver aldehyde oxidase in reductive metabolism of hydroxamic acids to amides. *Arch. Biochem. Biophys.* **247**:289–293.

DMD # 82453

- Suzuki T, Matsuura A, Kouketsu A, Hisakawa S, Nakagawa H, and Miyata N (2005) Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. *Bioorg. Med. Chem.* **13**:4332–4342 doi: 10.1016/j.bmc.2005.04.002.
- Vaught JB, McGarvey PB, Lee MS, Garner CD, Wang CY, Linsmaier-Bednar EM, and King CM (1981) Activation of N-hydroxyphenacetin to mutagenic and nucleic acid-binding metabolites by acyltransfer, deacylation, and sulfate conjugation. *Cancer Res.* **41**:3424–3429.
- Verma RP (2012) Hydroxamic acids as matrix metalloproteinase inhibitors. *EXS* **103**:137–176 doi: 10.1007/978-3-0348-0364-9\_5.
- Wagner JM, Hackanson B, Lübbert M, and Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. *Clin. Epigenet.* **1**:117–136 doi: 10.1007/s13148-010-0012-4.
- Wahl B, Reichmann D, Niks D, Krompholz N, Havemeyer A, Clement B, Messerschmidt T, Rothkegel M, Biester H, Hille R, Mendel RR, and Bittner F (2010) Biochemical and spectroscopic characterization of the human mitochondrial amidoxime reducing components hmARC-1 and hmARC-2 suggests the existence of a new molybdenum enzyme family in eukaryotes. *J. Biol. Chem.* **285**:37847–37859 doi: 10.1074/jbc.M110.169532.
- Wang K and Guengerich FP (2013) Reduction of aromatic and heterocyclic aromatic N-hydroxylamines by human cytochrome P450 2S1. *Chem. Res. Toxicol.* **26**:993–1004 doi: 10.1021/tx400139p.
- Whitby LG (1953) A new method for preparing flavin-adenine dinucleotide. *Biochem. J.* **54**:437–442.
- Wirth PJ, Dybing E, Bahr C von, and Thorgeirsson SS (1980) Mechanism of N-hydroxyacetylarylamine mutagenicity in the Salmonella test system: Metabolic activation of N-hydroxyphenacetin by liver and kidney fractions from rat, mouse, hamster, and man. *Mol. Pharmacol.* **18**:117–127.
- Wright SW and Corbett RL (1993) An Efficient Preparation of 2H-(5,4-b)Pyridoisothiazolone. *Org. Prep. Proced. Int.* **25**:247–249 doi: 10.1080/00304949309457957.
- Zhang J and Zhong Q (2014) Histone deacetylase inhibitors and cell death. *Cell. Mol. Life Sci.* **71**:3885–3901 doi: 10.1007/s00018-014-1656-6.

DMD # 82453

### Footnotes

DAS and MJ received funding from the European Union's Seventh Framework Program for research, technological development and demonstration under grant agreements nr. 241865 (SEtTReND).

DMD # 82453

## Figure Legends

**Figure 1. Metabolism of hydroxamic acids.** Hydroxamic acids can either undergo reduction to the corresponding amide or hydrolysis to the corresponding carboxylic acid. A hydrolysis of the amide to the carboxylic acid might be possible.

**Figure 2. Structures of all studied compounds.**

**Figure 3. *N*-reduction of benzhydroxamic acid, bufexamac, CP544439 and vorinostat in hepatic subcellular fractions.** Biotransformation assay consisted of 100 µg protein, 1 mM NADH and either 1.0 mM vorinostat and 4.8 % DMSO, 3.0 mM benzhydroxamic acid, 0.5 mM CP544439 and 4.0 % DMSO or 1.0 mM bufexamac and 8.0 % DMSO. Incubation was carried out for 15 min and stopped by addition of methanol. Activities are means ± S.D. of two biological determinations. (A) benzhydroxamic acid, (B) bufexamac, (C) CP544439, (D) vorinostat, \* = under limit of quantification, n.d. not detectable.

**Figure 4. *N*-reductive metabolism of benzhydroxamic acid in HEK-293 cells.** *N*-reductive activities of cells were determined as described in materials and methods. Results are presented as means ± S.D. (n=3). **(A)** Substrate dependent metabolism. Incubation time was 180 min. **(B)** Effect of mARC knockdown on *N*-reduction. HEK-293 cells were transfected with 20 nM mARC siRNA or non-targeting (NC) siRNA. The siRNA-mediated down-regulations of the proteins of interest were verified by western blot using anti-mARC1, anti-mARC2 or anti-calnexin antibody. Calnexin levels were used as loading control. mARC2-protein could not be detected. *N*-reductive activities were determined on day 4 after transfection. \*\*\* p < 0.001.

**Figure 5. Substrate concentration dependence for mARC1 (black) and mARC2 (white).**

Biotransformation assay consisted of 7.5 µg hmARC, 75 pmol CYB5B and 7.5 pmol CYB5R3. Incubation time was 15 minutes. Quantification was done by HPLC analysis. Activities are means ± S.D. of two biological determinations. (A) benzhydroxamic acid, (B) bufexamac, (C) CP544439, (D) vorinostat.

DMD # 82453

**Table 1: *N*-reduction of vorinostat, benzhydroxamic acid, bufexamac, CP544439, *N*-hydroxyphenacetin and benzamidoxime by the reconstituted recombinant mARC-system.**


Biotransformation assays were carried out as described in material and methods. Activities are means  $\pm$  S.D. of two biological determinations.

<sup>a</sup> LOQ = 0.9 nmol·min<sup>-1</sup>·mg protein<sup>-1</sup>, <sup>b</sup> LOQ = 3.5 nmol·min<sup>-1</sup>·mg protein<sup>-1</sup>.

Substrate		$K_m$ (mM)	$V_{max}$ (nmol·min <sup>-1</sup> ·mg protein <sup>-1</sup> )
vorinostat	mARC1	1.45 $\pm$ 0.37	46.3 $\pm$ 5.5
	mARC2	2.73 $\pm$ 0.18	19.3 $\pm$ 0.8
benzhydroxamic acid	mARC1	0.31 $\pm$ 0.11	73.7 $\pm$ 7.0
	mARC2	2.12 $\pm$ 0.28	313.5 $\pm$ 22.5
bufexamac	mARC1	1.09 $\pm$ 0.15	13.4 $\pm$ 1.1
	mARC2	1.07 $\pm$ 0.15	8.2 $\pm$ 0.7
CP544439	mARC1	0.25 $\pm$ 0.06	50.2 $\pm$ 4.4
	mARC2	-/-	-/- <sup>a</sup>
<i>N</i> -hydroxyphenacetin	mARC1	-/-	-/- <sup>b</sup>
	mARC2	-/-	-/- <sup>b</sup>
benzamidoxime	mARC1	0.63 $\pm$ 0.06	674.8 $\pm$ 25.1
	mARC2	0.54 $\pm$ 0.03	549.6 $\pm$ 12.1







DMD # 82453

Figure 1



DMD # 82453


Figure 2






DMD # 82453

Figure 3



DMD # 82453

**Figure 4**



DMD # 82453

Figure 5

